Tags

Type your tag names separated by a space and hit enter

α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database.
J Urol. 2019 08; 202(2):362-368.JU

Abstract

PURPOSE

A recent study demonstrated that tamsulosin increased the risk of dementia in patients with benign prostatic hyperplasia. However, this study had a number of limitations. We evaluated the association between α-blockers and dementia in patients with benign prostatic hyperplasia.

MATERIALS AND METHODS

From the National Health Insurance Service database we collected and analyzed data on α-blockers and dementia in the entire Korean adult population with benign prostatic hyperplasia between January 2011 and December 2011. These patients were followed until September 2017. We tested the effect of α-blockers on the risk of dementia using propensity score matched Cox proportional hazard regression models and Kaplan-Meier survival analysis.

RESULTS

During a mean ± SD followup of 1,580 ± 674.3 days all study inclusion and exclusion criteria were met by 59,263 patients with benign prostatic hyperplasia. In the unadjusted cohort the incidence of dementia in the tamsulosin, doxazosin, terazosin, alfuzosin and no medication cohorts were 17.97%, 18.55%, 20.64%, 17.62% and 22.60%, respectively. After propensity score matching the risk of dementia did not significantly differ in the tamsulosin cohort vs the doxazosin and alfuzosin cohorts (HR 1.038, 95% CI 0.960-1.121 and HR 1.008, 95% CI 0.925-1.098), respectively. Compared to the tamsulosin cohort the terazosin cohort had a higher risk of dementia (HR 1.112, 95% CI 1.052-1.196). However, the risk of dementia was significantly lower in the terazosin cohort than in the no medication cohort.

CONCLUSIONS

The study findings indicate that benign prostatic hyperplasia medication is not associated with a risk of dementia by duration of use or by type.

Authors+Show Affiliations

Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine , Ansan , Republic of Korea.Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine , Ansan , Republic of Korea.Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine , Ansan , Republic of Korea.Korea University Anam Hospital, Korea University College of Medicine , Seoul , Republic of Korea.Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine , Ansan , Republic of Korea.Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine , Ansan , Republic of Korea.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

30840545

Citation

Tae, Bum Sik, et al. "Α-Blocker and Risk of Dementia in Patients With Benign Prostatic Hyperplasia: a Nationwide Population Based Study Using the National Health Insurance Service Database." The Journal of Urology, vol. 202, no. 2, 2019, pp. 362-368.
Tae BS, Jeon BJ, Choi H, et al. Α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database. J Urol. 2019;202(2):362-368.
Tae, B. S., Jeon, B. J., Choi, H., Cheon, J., Park, J. Y., & Bae, J. H. (2019). Α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database. The Journal of Urology, 202(2), 362-368. https://doi.org/10.1097/JU.0000000000000209
Tae BS, et al. Α-Blocker and Risk of Dementia in Patients With Benign Prostatic Hyperplasia: a Nationwide Population Based Study Using the National Health Insurance Service Database. J Urol. 2019;202(2):362-368. PubMed PMID: 30840545.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database. AU - Tae,Bum Sik, AU - Jeon,Byeong Jo, AU - Choi,Hoon, AU - Cheon,Jun, AU - Park,Jae Young, AU - Bae,Jae Hyun, Y1 - 2019/07/08/ PY - 2019/3/7/pubmed PY - 2019/8/14/medline PY - 2019/3/7/entrez KW - 5-alpha reductase inhibitors KW - Republic of Korea KW - dementia KW - prostate KW - prostatic hyperplasia SP - 362 EP - 368 JF - The Journal of urology JO - J. Urol. VL - 202 IS - 2 N2 - PURPOSE: A recent study demonstrated that tamsulosin increased the risk of dementia in patients with benign prostatic hyperplasia. However, this study had a number of limitations. We evaluated the association between α-blockers and dementia in patients with benign prostatic hyperplasia. MATERIALS AND METHODS: From the National Health Insurance Service database we collected and analyzed data on α-blockers and dementia in the entire Korean adult population with benign prostatic hyperplasia between January 2011 and December 2011. These patients were followed until September 2017. We tested the effect of α-blockers on the risk of dementia using propensity score matched Cox proportional hazard regression models and Kaplan-Meier survival analysis. RESULTS: During a mean ± SD followup of 1,580 ± 674.3 days all study inclusion and exclusion criteria were met by 59,263 patients with benign prostatic hyperplasia. In the unadjusted cohort the incidence of dementia in the tamsulosin, doxazosin, terazosin, alfuzosin and no medication cohorts were 17.97%, 18.55%, 20.64%, 17.62% and 22.60%, respectively. After propensity score matching the risk of dementia did not significantly differ in the tamsulosin cohort vs the doxazosin and alfuzosin cohorts (HR 1.038, 95% CI 0.960-1.121 and HR 1.008, 95% CI 0.925-1.098), respectively. Compared to the tamsulosin cohort the terazosin cohort had a higher risk of dementia (HR 1.112, 95% CI 1.052-1.196). However, the risk of dementia was significantly lower in the terazosin cohort than in the no medication cohort. CONCLUSIONS: The study findings indicate that benign prostatic hyperplasia medication is not associated with a risk of dementia by duration of use or by type. SN - 1527-3792 UR - https://www.unboundmedicine.com/medline/citation/30840545/α-Blocker_and_Risk_of_Dementia_in_Patients_with_Benign_Prostatic_Hyperplasia:_A_Nationwide_Population_Based_Study_Using_the_National_Health_Insurance_Service_Database L2 - https://www.jurology.com/doi/full/10.1097/JU.0000000000000209?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -